Received Jul 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | P2443 | — |
patient received Twinrix 3rd dose earlier than recommended for the standard dosing schedule.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 82-year-old male patient who received HAB (Twinrix) (batch number P2443, expiry date 18-SEP-2027) for prophylaxis. Concomitant products included Hepatitis a vaccine inact, Hepatitis b vaccine rHBsAg (yeast) (Twinrix) and Hepatitis a vaccine inact, Hepatitis b vaccine rHBsAg (yeast) (Twinrix). On 08-MAY-2025, the patient received the 3rd dose of Twinrix. On 08-MAY-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too short (Verbatim: patient received Twinrix 3rd dose earlier than recommended for the standard dosing schedule.). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 07-JUL-2025 The pharmacist reported that an adult patient received Twinrix 3rd dose earlier than recommended for the standard dosing schedule. Twinrix first dose was on 07th March 2025, Twinrix second dose was on 12th April 2025 and Twinrix third dose was on 08th May 2025 which led to shortening of vaccination schedule. The vaccine administration facility was the same as primary reporter.
TWINRIX